Transparency

Epigenetics Drugs and Diagnostic Technologies Market Witnesses Rapid Research and Development of New-generation Diagnostic Technologies

Press Release   •   Oct 12, 2016 15:11 IST

Epigenetics is a regulatory mechanism that controls the gene expression without altering the genetic sequence. Epigenetic change in gene expression originates from the modification in transcription mechanism. Key components involved in the process of epigenetic transcriptory regulation include DNA methylation, histone modifications, micro RNA’s and non-coding RNA’s. However, our report focuses majorly on two types of epigenetic control factors: DNA methylation and covalent modification in histone proteins around which the DNA helix is wrapped. Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to various disease states. With the increase in aging population, rising incidence of oncology and non-oncology disorders, the demand for epigenetic diagnosis and drugs would also increase.

A rise in the number of aged people worldwide is helping the global epigenetics drugs and diagnostic technologies market grow rapidly. This, in turn, is attributable to the strong correlation between aging and various types of diseases. Between 2000 and 2050, the global geriatric population (60 years and above) is expected to double, the WHO reckons. The organization expects that 22% of the global population would comprise people aged 60 years or more. This age group carries a higher risk of diseases such as cancer.

Get PDF Brochure for more Professional and Technical industry insights:http://bit.ly/2dQv6aW

Owing to the increasing economic burden of diseases such as cancer and diabetes, governments across the world are advocating the adoption of early disease detection and diagnosis. Early cancer detection, especially, is being encouraged through screening kids such as Epi ProLung and Epi Procolon. This is aiding the growth of the global epigenetics drugs and diagnostic technologies market, states the report.

Epigenetic drugs are considered effective because they can help reverse aberrant gene expression, which could lead to various diseases. Histone Deacetylase (HDAC) and DNA methyltransferase (DNMT) are the inhibitors that regulate cellular expression. Of these, DNA methyltransferases hold a larger share in the market as they offer improved pathways to target cancerous cells.

The FDA-approved drugs that are currently available commercially include DNMT inhibitors, Vidaza (azacitidine) by Celgene and Dacogen (decitabine) from Eisai. These drugs have been approved for treating Myelodysplastic Syndrome (MDS). The epigenetics drugs market also features Zolinza (vorinostat) by Merck and Istodax (romidepsin) from Celegne, which are both HDAC inhibitors and have been approved for treating Cutaneous T Cell Lymphoma (CTCL).

However, epigenetics is stretching beyond oncology and is proving effective in several non-oncology indications, including arthritis and Alzheimer’s. This will give companies in the global epigenetics drugs and diagnostic technologies market a larger playing field.

North America represents the largest regional market for epigenetics. Over the forecast period of the report, it is expected that the region will continue to remain in a dominant position, accounting for about 50% of the global market for epigenetics. The demand for epigenetic drugs and diagnostic technologies in this region stems largely from the high incidence of cancer here.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/epigenetics-market.html

The global epigenetics drugs and diagnostic technologies market is estimated to rise at CAGR of 19.4% by 2018. The market was valued at US$3,080.8 mn in the year 2016 and is likely to reach US$4,067.8 mn by the end of 2018. With a CAGR of 18.5%, North America is likely to be the fastest growing region in the global epigenetic drugs and diagnostic technology market and is likely to hold 50% of the global revenue by 2018.

In Asia, the scope for this market’s growth is expanding rapidly. Asia accounts for about half all cancer cases diagnosed worldwide. This creates conducive conditions for the growth of the epigenetic drugs and diagnostics market in Asian countries, especially China, Japan, Australia, and South Korea, with Japan in the dominant position.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.